After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO

It’s been a busy week for Repare Therapeutics. On Tuesday, the cancer drug developer struck up an alliance with Bristol Myers Squibb (NYSE: BMY) that pays $65 million now and as much as $3 billion later, depending on the progress made in coming years. On Friday, Repare filed for an IPO that could bring in more capital much sooner.